-

12:16:19 PM

AFMD Stock News

AFMD - Affimed N.V.

11/22/21 7:11 AM

Nasdaq : AFMD

clinical trial

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1 st of 2 planned cycles at the recommended phase 2 dose of 10 8 cord blood-derived natural killer (cbNK) cells/kg pre-complexed with AFM13 No cases of serious adverse

RHEA-AI

neutral

11/12/21 7:01 AM

Nasdaq : AFMD

clinical trial

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three posters with preclinical data of its innate cell engagers (ICE®) are

RHEA-AI

neutral

11/10/21 6:30 AM

Nasdaq : AFMD

earnings

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022. AFM13 combination with NK cells: Updated data to be presented at company-sponsored event in mid-December 2021. AFM24 monotherapy: Identified recommended Phase 2 dose (480 mg weekly); expansion cohorts

RHEA-AI

neutral

11/09/21 6:30 AM

Nasdaq : AFMD

conferences

Affimed to Present at Upcoming Investor Conferences

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor

RHEA-AI

neutral

11/08/21 6:30 AM

Nasdaq : AFMD

clinical trial

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely non-small cell lung cancer, squamous cell carcinoma of the head and neck and colorectal cancer The study is

RHEA-AI

neutral

11/04/21 9:06 AM

Nasdaq : AFMD

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

Derived from Affimed’s ROCK ® platform, AFM28 binds selectively and with high affinity the surface antigens CD123 and CD16A AFM28 shows better killing of primary leukemic blasts in comparison to monoclonal antibodies which may lead to enhanced ADCC in patients In a preclinical toxicology study

RHEA-AI

neutral

11/04/21 9:05 AM

Nasdaq : AFMD

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13

A poster presentation featuring preclinical data on AFM28, a novel Innate Cell Engager developed for treatment of Acute Myeloid Leukemia and other CD123+ myeloid malignancies A poster presentation on AFM13 precomplexed NK cells that maintained biological activity and potency after one cycle of

RHEA-AI

neutral

10/29/21 6:30 AM

Nasdaq : AFMD

conferencesearnings

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 2021, and

RHEA-AI

neutral

10/01/21 8:05 AM

Nasdaq : AFMD

clinical trial

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been

RHEA-AI

neutral

09/08/21 6:30 AM

Nasdaq : AFMD

earnings

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022. AFM13 combination with NK cells: All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed; additional patients are being enrolled at the highest dose level to

RHEA-AI

neutral

1 2 3 4 5 6 Next

AFMD Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.affimed.com
Security nameAffimed N.V.
Issue typecs
SectorManufacturing
Sic code2834
Employees158
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

AFMD Description:

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.